Literature DB >> 11426948

Plasmodium falciparum: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro.

A E Tebo1, P G Kremsner, A J Luty.   

Abstract

In an attempt to identify parasite antigen-specific antibody isotype(s) mediating inhibition of growth in vitro, we tested unfractionated sera and their corresponding purified antibody isotype-containing fractions in in vitro assays with asexual-stage parasites of Plasmodium falciparum in the presence or absence of monocytes. Using affinity purification techniques we fractionated individual and pooled serum samples from semi-immune Gabonese adults, to obtain samples containing either IgG1, 2, 3, and 4, IgG1, 2, and 4, or IgG3 alone, and a non-IgG fraction. Antibodies were quantified spectrophotometrically and the presence of different isotypes in individual fractions was confirmed by protein gel electrophoresis. In the absence of monocytes, we observed inhibition of parasite growth with whole serum and varying levels of either growth enhancement or inhibition with purified Ig-containing fractions. When used in a standardized assay of antibody-dependent cellular inhibition (ADCI) with a monocyte:infected erythrocyte ratio of 1:1, seven of eight serum samples inhibited growth to a mean level of 42%, and the different Ig-containing fractions displayed varying mean levels of inhibition: IgG3, 44%; IgG1--4, 22%; IgG1, 2, and 4, 10%; and non-IgG, - 10%. The results suggest that, among the different isotypes present in the serum of semi-immune individuals, parasite antigen-specific IgG3 in particular may play an important role in controlling parasitemia via an ADCI mechanism involving monocyte- derived mediators. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11426948     DOI: 10.1006/expr.2001.4619

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  40 in total

1.  Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies.

Authors:  Janine Stubbs; Sope Olugbile; Balam Saidou; Jacques Simpore; Giampietro Corradin; Antonio Lanzavecchia
Journal:  Infect Immun       Date:  2010-12-28       Impact factor: 3.441

Review 2.  Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines.

Authors:  Godfree Mlambo; Nirbhay Kumar
Journal:  Eukaryot Cell       Date:  2008-09-19

3.  Predicting antidisease immunity using proteome arrays and sera from children naturally exposed to malaria.

Authors:  Olivia C Finney; Samuel A Danziger; Douglas M Molina; Marissa Vignali; Aki Takagi; Ming Ji; Danielle I Stanisic; Peter M Siba; Xiawu Liang; John D Aitchison; Ivo Mueller; Malcolm J Gardner; Ruobing Wang
Journal:  Mol Cell Proteomics       Date:  2014-07-14       Impact factor: 5.911

4.  Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.

Authors:  Akram Abouie Mehrizi; Niloufar Rezvani; Sedigheh Zakeri; Atefeh Gholami; Laleh Babaeekhou
Journal:  Med Microbiol Immunol       Date:  2018-02-03       Impact factor: 3.402

5.  Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assays.

Authors:  Danny W Wilson; Brendan S Crabb; James G Beeson
Journal:  Malar J       Date:  2010-06-03       Impact factor: 2.979

6.  A distinct peripheral blood monocyte phenotype is associated with parasite inhibitory activity in acute uncomplicated Plasmodium falciparum malaria.

Authors:  Pattamawan Chimma; Christian Roussilhon; Panudda Sratongno; Ronnatrai Ruangveerayuth; Kovit Pattanapanyasat; Jean-Louis Pérignon; David J Roberts; Pierre Druilhe
Journal:  PLoS Pathog       Date:  2009-10-23       Impact factor: 6.823

7.  IL4 gene polymorphism and previous malaria experiences manipulate anti-Plasmodium falciparum antibody isotype profiles in complicated and uncomplicated malaria.

Authors:  Piyatida Tangteerawatana; Hedvig Perlmann; Masashi Hayano; Thareerat Kalambaheti; Marita Troye-Blomberg; Srisin Khusmith
Journal:  Malar J       Date:  2009-12-10       Impact factor: 2.979

8.  Heritability of antibody isotype and subclass responses to Plasmodium falciparum antigens.

Authors:  Nancy O Duah; Helen A Weiss; Annette Jepson; Kevin K A Tetteh; Hilton C Whittle; David J Conway
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

9.  Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

Authors:  Sodiomon B Sirima; Alfred B Tiono; Alphonse Ouédraogo; Amidou Diarra; André Lin Ouédraogo; Jean Baptiste Yaro; Espérance Ouédraogo; Adama Gansané; Edith C Bougouma; Amadou T Konaté; Youssouf Kaboré; Abdoulaye Traoré; Roma Chilengi; Chilengi Roma; Issiaka Soulama; Adrian J F Luty; Pierre Druilhe; Simon Cousens; Issa Nébié
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

10.  The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria.

Authors:  David Courtin; Mayke Oesterholt; Harm Huismans; Kwadwo Kusi; Jacqueline Milet; Cyril Badaut; Oumar Gaye; Will Roeffen; Edmond J Remarque; Robert Sauerwein; André Garcia; Adrian J F Luty
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.